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Abstract
Attention-deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder affecting approximately 11 percent of
the country's children and adolescents, between the ages
four to seventeen years. Stimulant medications such as methylphenidate and amphetamines are the first-line of treatment
for ADHD. The increasing use of these stimulant medications
has resulted in increased media attention and raised questions about their efficacy and safety. This review focuses on
the history of stimulant use in ADHD, the disease's pathophysiology, the long-term benefits of pharmacotherapy, and
the possible subsequent adverse effects associated with prolonged stimulant use in children and adolescents suffering
from ADHD. Furthermore, we will highlight the important
role of the pharmacist in both the long-term management of
ADHD patients and in preventing the misuse/abuse of prescription stimulant medications. In addition, we briefly discuss the role of non-stimulants in the treatment of ADHD.
Overall, a detailed review of the available literature suggests
that there is an urgent need to conduct well-designed, longterm studies to more clearly understand the benefits and
adverse effects associated with stimulant and non-stimulant
use in the treatment of ADHD in children and adolescents.
Background of ADHD
Attention-deficit hyperactivity disorder (ADHD) is a neurobehavioral disorder characterized by developmentally.inappropriate levels of hyperactivity, impulsivity and lack of
focus and attention to the task on hand. As of 2011, approximately 6.4 million children and adolescents between the ages
4 to 17 years have been diagnosed with ADHD in the United
States.1 The prevalence of ADHD in children has steadily increased and varied by state ranging from 5.6 percent to 18. 7
percent in 2011. Importantly, it has been found that children
with ADHD, if left untreated, have poor academic performance, low self-esteem, frustration and problems with social
relationships.2 Further, it has been observed that untreated
children are at increased risk of developing several types of
psychiatric disorders in adulthood such as conduct disorder,
mood disorder, substance use disorder and anxiety disorder.1 Thus, it is extremely important to both diagnose and
treat children and adolescents with ADHD.
The most common treatment option for ADHD is stimulants,
such as amphetamines and methylphenidate. 2 In many children, stimulants reduce hyperactivity and impulsivity to improve their ability to focus and learn. Additionally, long-term
treatment with stimulants has shown to improve academic
performance and reduce the incidence of psychiatric disorders in adulthood. Despite these beneficial effects of stimulants, there is some concern regarding potential side effects
associated with chronic, long-term use. Non-stimulants are
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viable second-line agents for treatment of ADHD, which can
be used to avoid the side effects of stimulants. The major focus of this review is on the benefits and challenges associated
with use of stimulants in treatment of ADHD in children and
adolescents. The use of non-stimulants in ADHD treatment is
also briefly discussed.
History of Stimulants
Amphetamine was synthesized in the laboratory by G.A. Alles
in 1927. Alles reported for the first time that amphetamines
could produce insomnia or arousaJ.3 Subsequently, it was
also shown that administration of amphetamines led to improved performance on intelligence tests, stress relief, concentration enhancement and better intellectual performance.
In addition, amphetamine was investigated as a medication
for asthma in the 1920s and was used in the United States in
the early 1930s for congestion and respiratory disorders.4
During World War II, amphetamines were used as 'energy
pills' for allied forces. 3 Amphetamines could be obtained with
or without a prescription in the '50s and '60s to treat obesity,
depression, narcolepsy and encephalitic Parkinsonism treatment. The widespread use of amphetamines resulted in significant abuse of the medication for recreational purposes
resulting in development of amphetamine dependence in
otherwise healthy individuals. In order to stem the misuse/
abuse of amphetamines, the government made amphetamine
a schedule II drug in 1972, which limited its sale only to individuals for treatment of their medical condition and required
patients to obtain a prescription in order to possess amphetamines. The classification of amphetamine as a schedule
II drug ultimately resulted in a decline in amphetamine use
for medical conditions, although its abuse for recreational
purposes continued.s
Currently, amphetamines are medications of choice for the
treatment of ADHD.3.4 The first amphetamine on the market
was Benzedrine®, a racemic a-methylphenethylamine, registered by the pharmaceutical company Smith, Kline, and French.3
Later, the same company synthesized both the dextro- (d-) and
levo- (I-) isomers and began to market d-amphetamine as Dexedrine® in 1937, as the more potent isomer. Clinical trials in the
1970s showed that both the I-isomer (Cydril®) and the d-isomer
were clinically effective in the treatment of ADHD. The use of
a-methylphenethylamine began to decrease dramatically after a
report by Gross in 1976 showed that the racemate was less effective than d-amphetamine.6 Currently, I-amphetamine is only
used in mixed salt ADHD medications which are a three to one
enantiomeric mixture of d-amphetamine and I-amphetamine
respectively. 3 This mixture is available as immediate and extended-release Adderall®. Administering an extended-release
stimulant allows for the patient to take the medication under
parental supervision in the morning and reduces the han-

THE PHARMACY AND WELLNESS REVIEW

49

CNS

Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents: Benefits and Challenges

dling of children and adolescents. The extended-release
fo rmulation has also shown to decrease abuse potential by
introducing tamper evident tactics to the medications. Recently, the prodrug lisdexamfetamine dimesylate (Vyvanse®)
has been used in ADHD management in children (age 6-12
years), adolescents (age 13-17 years) and adults. Lisdexamfetamine dimesylate contains the naturally occurring
L-lysine bound covalently to d-amphetamine through an amide-linking group. It is metabolized in the bloodstream by red
blood cells to yield the stimulant ct-amphetamine and the
natural amino acid L-lysine in a rate-limited enzymatic hydrolysis. As a prodrug, lisdexamfetamine diverts abuse by
creating a slower release of ct-amphetamine, thus decreasing
the pleasurable effects associated with the abuse of the drug.
Overall, the availability of amphetamine in different
formulations such as a prodrug and as an extended-release
formulation has helped in the treatment of ADHD by improving adherence and limiting its abuse.

Pathophysiology
Attention-deficit hyperactivity disorder is caused by deficient
maturation in the cortical and subcortical structures of the
brain.7 This disease state specifically affects the prefrontal
cortex (PFC), the part of the brain that is responsible for
regulating attention, behavior and emotions. The PFC is also
interconnected with other critical structures, such as the
basal ganglia. The basal ganglia consists of subcortical nuclei
that are mainly responsible for suppressing excessive voluntary motor function through its communication with the PFC.
Neuro-imaging studies conducted in children diagnosed with
ADHD have reported a decrease in gray matter volume of the
globus pallidus, a major component of the basal ganglia. 7-9 It
is hypothesized that the decreased functioning of the basal
ganglia is responsible for the hyperactivity symptoms, such
as tremors and jerking, commonly observed in ADHD
patients. Overall, lesions or malformations in the PFC can
dramatically decrease attention span and attenuate concentration while heightening voluntary motor function.
Pprefrontal cortex function is mediated by microcircuits of
glutamatergic pyramidal cells interacting with gammaaminobutyric acid (GABA)ergic inhibitory interneurons. The
pyramidal cells are activated by N-methyl-D-aspartate
(NMDA) synapses on dendritic spines and help maintain the
necessary neurotransmission for working memory or inhibiting inappropriate motor behaviors. Intensity of the NMDAmediated signaling is modulated/fine-tuned by endogenous
neurotransmitters, such as norepinephrine (NE) and dopamine (DA). Increased stimulation of NE and DA receptors
(i.e., u2 and Dl, respectively) facilitates improved connectivity between different brain regions involved in attention
and learning. Norepinephrine binds to u2A adrenergic
receptors and thereby increases attention toward stimuli of
interest (signal).10 At the same time, dopamine binds to Dl
dopaminergic receptors and helps suppress activation of PFC
circuits due to competing or distracting stimuli (noise).io.11
These neurotransmitters thus amplify signal: noise ratio and
help in improving focus and attention toward stimuli of interest. In ADHD patients, synaptic levels of NE and DA in the
PFC are decreased. These deficits can be corrected by admin-
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istering stimulant and non-stimulant medications, which
help in either increasing NE/DA concentration and/or increasing respective receptor stimulation.

Pharmacology
Norepinephrine and DA are cleared from the neuronal synapses via uptake transporters located on presynaptic nerve
terminals; therefore, the most efficient way to increase synaptic DA/NE levels is to block their uptake via these transporters.12 Central nervous system (CNS) stimulants, like
methylphenidate and amphetamine, dramatically increase
the amount of extracellular NE and DA available in the PFC
via blockade and/or reversal of the norepinephrine uptake
transporter (NET) and dopamine uptake transporter
(DAT).1 2 In addition, amphetamines also disrupt vesicular
storage of these neurotransmitters in the presynaptic
terminal, allowing them to accumulate in the cytoplasm. Furthermore, amphetamine inhibits the degradative enzymes
monoamine oxidase A and B (MAO-A, MA0-8), which allows
cytosolic accumulation and promotes release in the synapse.12 In addition, the U.S. Food and Drug Administration
(FDA) has approved non-stimulants for the treatment of
ADHD such as atomoxetine, clonidine and guanfacine. Atomoxetine selectively inhibits the presynaptic reuptake of NE
in the PFC, thus increasing synaptic NE levels. In contrast,
guanfacine and clonidine are a2 adrenergic receptors agonists and thus help in increasing activity of u2 adrenergic
receptors. Non-stimulant medications are considered second
-line treatments and are reserved for patients who are unresponsive to stimulants or in whom stimulants cannot be
used, for example patients with cardiovascular abnormalities
or patients predisposed to addiction/substance abuse. Overall, this stimulant/non-stimulant-induced increase in DA/NE
receptor activity improves neuronal communication by amplifying the signal to noise ratio; and thus, ultimately results
in improved attention and working memory. However, increasing concentrations of DA/NE is beneficial up to a certain
point. Excessive increase in DA/NE levels results in suppression of neuronal firing in the PFC networks and can ultimately lead to worsening of ADHD symptoms.a Thus, there is
an "inverted U" -shaped dose dependent relationship between PFC function and DA/NE levels.
Beneficial Effects of Chronic Stimulant Use
Long-term use of stimulants in children and adolescents diagnosed with ADHD does have significant beneficial effects.
These effects are apparent in children/adolescents who are
between 6 and 18 years old taking methylphenidate and
those who are older than 3 years old taking amphetamine.13,14 Studies have shown that there is a positive correlation between ADHD medications and academic performance
in elementary school. Children, ages 9.11±1.22 years, who
were treated with stimulants for at least one year outperformed their control counterparts in all tests measuring academic achievement.ls Additionally, longitudinal case-control
prospective studies of ADHD patients (males and females
aged 6-18 years) were conducted to assess the psychiatric
consequences of long-term stimulant use. Results suggest
that lifetime stimulant treatment may prevent psychiatric
outcomes such as antisocial, addictive, mood and anxiety
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disorders.16.11 Addiction and subsequent substance use disorder (SUD) is precipitated by untreated ADHD. For example, in
a longitudinal study of boys (aged 6 to 17 years) with ADHD,
incidences of SUD was compared in young adults without
ADHD (Group 1), young adults with untreated ADHD (Group
2), and young adults with ADHD treated with stimulants
(Group 3). Baseline SUD was initially recorded and remeasured after 4 years. In this study, SUD consisted of alcohol,
marijuana, hallucinogen, stimulant and cocaine abuse. Rates
of SUD were as follows: Group 1 (75%), Group 2 (25%) and
Group 3 (-18%). Medicated children with ADHD were almost 85 percent less likely to develop a SUD. These data suggest that untreated ADHD patients could have an increased
substance abuse potential and that pharmacotherapy may
protect children from this risk.18,19 Therefore, it is important
to treat ADHD to minimize this increase in substance abuse
potential. Non-stimulants, commonly prescribed to adults
and children with ADHD, have not been extensively studied
in clinical trials to assess their long term efficacy.20 Overall,
studies suggest that pharmacological treatment of ADHD in
general can lead to improved quality oflife.

Acute and Long-Term Side Effects
Central nervous system stimulants are considered first-line
therapy as they have been shown to be more effective than
non-stimulants in managing ADHo.21 The use of stimulants
for treating ADHD has increased dramatically from decade to
decade. One study has reported an increase in stimulant use
for treatment of ADHD from 0.9 to 3.4 per 100 children between 1987 to 1997 .22 However, like all other medications,
stimulants are associated with acute and long-term side effects. Acute side effects of stimulants include nervousness,
insomnia, decreased appetite, headache, stomachache, nausea and dizziness one hour after oral administration. These
symptoms are possibly due to an increase in sympathetic
activity resulting from increased NE levels.20
In addition, long-term administration of stimulant medications is associated with possible negative mental and physical consequences. Addiction is one of the most common
chronic side effects of stimulant use. Methylphenidate and
amphetamine increase concentrations of NE and DA in the
brain, which results in a sense of alertness, increased energy
and euphoria. Abuse of stimulant medications by taking them
more frequently, or in doses higher than prescribed, can result in stimulant dependence in ADHD patients. Certain genetic polymorphisms may also increase predisposition to
stimulant abuse.23 These genetic quirks alter the function of
certain proteins involved in the reward pathways - networks
in the brain responsible for motivation and incentive drive.
Specifically, ghrelin is a peptide responsible for activating
appetite. Polymorphisms in the pre-proghrelin and GHS-RlA
(GHSR) gene equate to weight gain and increased alcohol/
smoking use in humans. A case control analysis showed that
individuals with a single nucleotide polymorphism to the
GHSR gene had a higher Addiction Severity Interview
composite score of drug use.23 Genetic alteration in ghrelin is
currently not a diagnostic indication for amphetamine dependence; however, the role it has on addiction should not
be ignored. This observation allows for possible drug develJuly 2014 Volume 5, Issue 3
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opment for the treatment of such addictive behaviors. Because of the high incidence of abuse, stimulant medications
come with black box warnings which remind patients of the
risk of dependence and that illicit use of stimulants is strictly
prohibited.24.2 5 Non-stimulants, although not medications of
choice for treatment of ADHD, are safer alternatives to stimulants because they do not present the same risk for abuse
and addiction.26
Adverse cardiovascular events are widely associated with
the chronic use of stimulants.27 Methylphenidate and amphetamine are sympathomimetics, analogs that stimulate the
sympathetic nervous system, which if abused can lead to
hypertension, tachycardia, vasoconstriction, arrhythmias,
coronary artery disease, myocardial ischemia and cardiomyopathy. Therefore, adolescents with underlying cardiac
abnormalities or with a family history of unexplained syncope, angina and other cardiac issues should take extreme
caution with using CNS stimulants. Long-term studies exploring the relationship between methylphenidate/amphetamine
use and cardiovascular events indicate that there were small
but significant increases in blood pressure and heart rate
without significant changes in the electrocardiograms after a
six-month to one-year treatment.20 However, these studies
conclude that these cardiac changes are predictable and
quite benign. Ways to minimize cardiovascular events include avoiding stimulant abuse and only titrating the dose as
needed for effective therapy. Patients should also avoid use
of any other NE/DA reuptake inhibitors or MAO inhibitors as
they can enhance the hypertensive effects of stimulants. Atomoxetine may also increase blood pressure with short and
long-term treatment. Although, long-term use of extended
release guanfacine leading to cardiovascular events is uncommon, it still remains contraindicated in children with
clinically significant cardiovascular history.
Effects of stimulants on growth are a major issue of debate in
the treatment of ADHD children. Stimulants have been observed to decrease growth rate in newly medicated patients.
Some formulations, such as the transdermal and osmotic
controlled release oral delivery system methylphenidate,
have been proven to affect rate of weight gain and linear
growth.ZOThese data, however, need to be confirmed by further
studies. Atomoxetine has also showed minimal effect on
height.20 An increase in tics/Tourette's syndrome is sometimes
observed in children with ADHD who are being treated with
stimulants. However, there is no current data that support the
exacerbation of tics/Tourette's syndrome is due to use of
stimulant medications. One possible reason for the above observation could be that half of the children with chronic tics/
Tourette's syndrome potentially qualify as an ADHD patient as
well.20 Nevertheless, developing children and those with comorbid conditions such as Tourette's must be closely monitored during the course of stimulant treatment. Interestingly, a
meta-analysis of nine studies demonstrated that tics and symptoms of Tourette's symptoms are effectively attenuated upon
administration of non-stimulant medications such as a2 agonists and atomoxetine in children with comorbid ADHD.28
Regardless, stimulants such as methylphenidate appear to provide the best alleviation of ADHD symptoms.
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A study has reported dopaminergic and serotonergic toxicity
in primates after six weeks of treatment with amphetamine
at doses used to treat ADHD patients.29 This study prompts a
concern that chronic therapeutic doses of amphetamines can
lead to similar toxicity in ADHD patients. Koeller et al. suggests that these neurotoxicities may not be observable in
ADHD patients due to the fact that diseases such as Parkinson's disease require 80 to 90 percent depletion in dopaminergic neurons before signs and symptoms appear.
Despite these alarming reported amphetamine-induced toxicities in primates, it is possible that such toxicities may not
appear in ADHD patients due to a few key reasons. Unlike
primates, humans are able to prevent the neurotoxic accumulation of amphetamines through their extensive metabolism. Also, human and nonhuman subjects such as primates
may differ in their sensitivity to amphetamine-induced toxicity. Finally, it is possible that amphetamine-induced toxicity
may be observed only in healthy human subjects who abuse
amphetamine for recreational purposes and do not actually
suffer from ADHD.29 Patients suffering from ADHD have a
deficiency of dopamine and norepinephrine and therefore
may be less vulnerable to amphetamine-induced toxicity
compared to healthy subjects. In summary, further studies
are required to fully understand the implications of chronic
stimulant exposure in ADHD patients.
The Role of the Pharmacist in Management of ADHD and
Abuse
With pharmacists being the most accessible health care professionals, it is crucial for pharmacists to know both diagnostic and treatment guidelines. Guidelines for diagnosis have
been established by the American Association's Diagnostic
and Statistical Manual, also known as DSM-5. In regard to
treatment, the National Collaborating Center for Mental
Health recommends that initial treatment begins with stimulants, and more specifically methylphenidate.3o When a patient initiates this therapy, it is important as pharmacists to
ensure the patient is starting with a low dose with the potential to titrate up as needed. Supplemental treatment such as
behavioral therapy should also be initiated. In regard to
these guidelines, it is crucial for pharmacists to understand
that there is no specific treatment algorithm for the treatment of ADHD. Stimulants are considered first-line whereas
non-stimulants can be used as second-line therapy. Regardless of which treatment option is initiated, the therapy
should start with low doses with the intent to titrate up as
needed and always be supplemented with nonpharmacologic
management such as behavioral therapy and parent training.
Considering that ADHD is a chronic disease that is diagnosed
in childhood and continues well into adulthood, there is a
need to carefully monitor and manage the therapy in these
patients to maximize the beneficial effects and minimize the
adverse effects. The pharmacist can play a pivotal role in the
long-term management of these patients. The first goal of
therapy should be to manage the patient's symptoms such as
hyperactivity, inability to concentrate and lack of attention.
As described above, stimulant medications compared to nonstimulant medications are more effective in managing ADHD
patients. Also, another important goal of the pharmacist
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should be to minimize acute and long-term side effects resulting from medications prescribed for ADHD. This can be
achieved through appropriate patient education and counseling. Patients must be made aware of the potential side effects
such as tachycardia, palpitations, mood changes, agitation,
insomnia and headaches.13 Furthermore, pharmacists need
to stress to patients the importance of medication adherence.
Medications must be taken as they are prescribed. Patients
must also be made aware that taking the medication more
frequently or in larger amounts can result in adverse longterm consequences such as development of drug dependence
and/or neurotoxicity. Finally, it is important for the pharmacist to consistently monitor and record changes in weight,
height and psychological status of these ADHD patients. The
ultimate goal of ADHD treatment should be to improve the
quality oflife of the patient.
As health care professionals, it is imperative to monitor patients for important parameters such as weight, growth, psychological status, efficacy of medication, compliance and adverse events such as cardiovascular issues and mental status
alterations. To avoid these side effects and ensure quality of
life for ADHD patients, it is crucial that pharmacists educate
parents and other family members, as well as have them inform their teachers at school. This education will help with
patient adherence as well as increase monitoring for adverse
effects.
Another important role of the pharmacist in the management
of ADHD patients is in preventing drug interactions. As a
pharmacist, it is vital to review medication lists to ensure the
patient is not at high risk for an adverse event. For example,
a patient who is taking anti-arrhythmic medication may be at
a greater risk for a cardiovascular event due to stimulant
therapy for ADHD. It is important that pharmacists know and
understand alternative pharmacologic and nonpharmacologic
approaches for treatment of ADHD. In addition to nonstimulant medications, there are also many nonpharmacologic
therapies, such as cognitive behavioral therapy, family therapy. parent training and social skills that can be useful in
these situations. These can be aided by services offered
through schools as well as follow-up visits with the prescriber.31 !n summary, as health care professionals, it is imperative to assess the efficacy of medication and compliance,
and to prevent adverse effects including potential drug interactions.
Due to the benefits of stimulants such as alertness and focus,
there is a larger abuse potential in those with or without a
prescription. Abuse of stimulant medications can lead to
development of drug dependence in ADHD patients.32 This
dependence can then lead to psychosocial alterations in patients who have already been diagnosed with another psychiatric disorder. This helps explain why ADHD medications
have a black box warning and require strict monitoring.
Pharmacists are the final line of defense against abuse and
overuse of these medications and can monitor the exposures
each month. Pharmacists can utilize tools such as Ohio Automated Rx Reporting System (OARRS) to track what controlled prescriptions a patient has, the quantity filled and
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how often they have filled a specific medication. Thus, this
system may help control abuse by allowing pharmacists to
identify abnormal filling tendencies of these medications and
contact the prescribing doctor to ensure the integrity of the
prescription. In addition to monitoring data that suggests
abuse, it is important that the pharmacist look out for psychosocial behavioral changes and/or withdrawal symptoms.
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6.

7.

Due to the pharmacological effects of stimulants such as increased alertness, increased energy and euphoria, there is a
large potential for abuse of prescription stimulants by individuals without a prescription. In fact, abuse of stimulant
medications is on the rise among college students for it is
believed to improve performance on examinations. There are
reports of prescription medications being sold to classmates
because of their desired effects. Furthermore, there are reports that students are falsely reporting signs and symptoms
of ADHD to their health care providers in order to obtain prescription stimulants.32 Despite regulations to monitor to
whom these prescriptions are dispensed, it is much harder to
regulate what patients do with their prescriptions. As described above, stimulant-induced neurotoxicities are more
likely to occur in healthy subjects compared to patients with
ADHD. Importantly, individuals abusing ADHD medications
not prescribed to them will not be monitored and are therefore more vulnerable, compared to ADHD patients, to adverse consequences of these stimulant medications. In the
future, all of the challenges associated with prescription
stimulants such as abuse, misuse and malingering will need
to be collectively addressed by pharmacists and other health
care providers.29

Conclusion
There are warranted and appropriate uses of stimulants such
as amphetamines and methylphenidate; however, these
should be used with extreme caution. These stimulants have
shown the ability to improve the patient's quality of life
when therapy parallels the strict guidelines such as those set
by DSM. Appropriate therapy helps eliminate unnecessary
exposure to adverse effects as well as misdiagnoses. Further,
the role of non-stimulant medications needs to be further
investigated to provide safe alternatives to ADHD therapy for
those who have pre-existing conditions or sensitivities toward stimulants that disqualify them from stimulant therapies. Finally, it is imperative that the long-term effects, both
beneficial and adverse, of stimulants and non-stimulants be
evaluated in prospective cohort studies in order for prescribers and pharmacists to be aware that the added benefits of
therapy outweigh the potential short-term and long-term
risks.
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